Breast cancer chemotherapy drugs, such as doxorubicin (Dox), are immunogenic cell death inducers that promote DC maturation, facilitating TIL infiltration and NK cell recruitment, increasing the secretion of proinflammatory cytokines (IFN-γ, TNF-α, and IL-6), and resulting in enhanced antitumor activity 115. This evidence concerns the gene TNF and breast carcinoma.